KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $659.8 million.

  • Recursion Pharmaceuticals' Cash & Equivalents rose 54.29% to $659.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $659.8 million, marking a year-over-year increase of 54.29%. This contributed to the annual value of $594.4 million for FY2024, which is 51.79% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Cash & Equivalents stood at $659.8 million for Q3 2025, which was up 25.66% from $525.1 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Cash & Equivalents' 5-year high stood at $659.8 million during Q3 2025, with a 5-year trough of $214.1 million in Q1 2021.
  • Moreover, its 3-year median value for Cash & Equivalents was $473.1 million (2023), whereas its average is $466.9 million.
  • In the last 5 years, Recursion Pharmaceuticals' Cash & Equivalents skyrocketed by 137.23% in 2022 and then crashed by 37.37% in 2024.
  • Recursion Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $285.1 million in 2021, then spiked by 92.87% to $549.9 million in 2022, then dropped by 28.79% to $391.6 million in 2023, then skyrocketed by 51.79% to $594.4 million in 2024, then soared by 54.29% to $659.8 million in 2025.
  • Its Cash & Equivalents stands at $659.8 million for Q3 2025, versus $525.1 million for Q2 2025 and $500.5 million for Q1 2025.